Tokyo Metropolitan Institute of Medical Science

Chugai Seiyaku Kabushiki Kaisha

Other

Kagoshima University

Peptidream Inc.

Juridical Foundation the Chemo-sero-therapeutic Research Institute

Kumamoto University

Nagasaki University

Ehime University

The Chemo-sero-therapeutic Research Institute

Km Biologics Co., Ltd.

Japan As Represented by Director-general of National Institute of Infectious Diseases

National Institutes of Biomedical Innovation, Health and Nutrition

Hokkaido University

Nobelpharma Co., Ltd.

Michinori Kohara

Masaaki Sato

Kyoko Kohara

Chise Mukaidani

Takaji Wakita

Izumu Saito

Hiroyuki Kouji

Takenao Odagami

Patrick Reid

Hiromichi Yonekawa

Koichi Jishage

Masaki Ohuchi

Keiichi Masuya

Choji Taya

Yosuke Kawase

Yasuhiro Yasutomi

Satoko Hamamura

Kiichi Kubota

Takahiro Sanada

Hiroki Oshita

Hideki Hasegawa

Masayuki Tsuchiya

Koji Ishii

Tomohiro Nishimura

Takashi Miyazaki

Taizou Kamishita

Yasuhiko Hayakawa

Masayuki Sudo

Kazunari Taira

Kouichi Morita

Kiyoshi Hayakawa

Yoichi Hiasa

Osamu Yoshida

Fukashi Murai

Tsubasa Munakata

Daisuke Yamane

Fumihiko Yasui

Hiroshi Ohmori

Junichi Matsuzaki

Tetsuya Toyoda

Kazuhiro Higashi

Yumiko Shiogama

Masaaki Arai

Hiroshi Kida

Yoshihiro Sakoda

Toshio Murakami

The present invention provides a pharmaceutical composition for treating hepatitis B. The present invention provides a composition for inhibiting the replication of hepatitis B virus and a pharmaceutical composition for treating hepatitis B virus infection, each comprising an inhibitory substance against microRNA binding to the 5' epsilon signal sequence in the pregenomic RNA of hepatitis B virus.

Composition for inhibiting replication of hepatitis B virus

The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.

Dengue virus vaccine

An electrode for electroporation comprising a plurality of electrode needles, wherein first polarity electrode needles, an electrode needle holding portion, and a syringe holding portion are provided; two or more first polarity electrode needles project from a bottom surface of a lower structural body of an outer frame support of the electrode needle holding portion toward an electroporation target side; the bottom surface of the lower structural body of the outer frame support is provided with a hole for syringe needle insertion and removal communicating with a syringe holding portion side; the syringe holding portion is provided on a side opposite to the electroporation target side of the electrode needle holding portion; and the syringe holding portion has a path for syringe needle insertion and removal, at least a portion of the path for syringe needle insertion and removal being provided with an electro-conductive portion for a second polarity.

Electrodes for electroporation

The present invention relates to a hepatitis B vaccine composition for spray-administration to nasal mucosa for preventing and treating hepatitis B, which comprises hepatitis B antigen and carboxy vinyl polymer.

Nasal hepatitis B vaccine composition and method for producing same

The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of:

Urokinase-type plasminogen activator transgenic mouse

Disclosed is a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. Also disclosed are hemagglutinin-binding peptides comprising a polypeptide having any of the following amino acid sequences (i) to (iv):

Hemagglutinin-binding peptide

Object of the present invention is to provide a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. The present invention provides, for example, a hemagglutinin-binding peptide comprising a polypeptide having any of the following amino acid sequences (i) to (iv):

CBP/&#x3b2;-catenin inhibitor shows a superior defibrosing effect for Cre/loxP/HCV-MxCre transgenic mouse which is an animal experiment model of hepatic fibrosis, and useful as a prophylactic or therapeutic drug for hepatic fibrosis.

Prevention or treatment agent for hepatic fibrosis

The present invention can induce stronger cellular immunity to hepatitis C and provide a treatment means and a prevention means that are effective in completely eliminating the hepatitis C virus (HCV). Provided is a pharmaceutical composition for the treatment and/or prevention of hepatitis C, said composition comprising a recombinant vaccinia virus (a) and a recombinant vector (b) and characterized in that after one of the recombinant vaccinia virus (a) and the recombinant vector (b) is administered for initial immunity, the other is administered for additional immunity. The recombinant vaccinia virus (a) contains an expression promoter and all or a portion of the cDNA of the HCV genome. The recombinant vector (b) contains an expression promoter and all or a portion of the cDNA of the HCV (where the cDNA contained in the recombinant vector (b) has a different base sequence than that included in the recombinant vaccinia virus (a)).

Pharmaceutical composition for treatment and/or prevention of hepatitis C

The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of: (i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof; (ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo; (iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and (iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.

Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above.

Recombinant vaccinia virus having hepatitis C virus gene

The present inventors focused on siE sequences that have been thought to show RNAi activity against HCV viral RNAs, and mainly selected the D5-50 and D5-197 regions present within the IRES region, and carried on the analysis. As a result, the present inventors successfully identified siRNA sequences that exhibit a more effective RNAi activity against hepatitis C virus RNAs. Furthermore, the siRNAs were demonstrated to have a significant inhibitory effect on HCV propagation in an in vivo system.

Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus

A polynucleotide encoding the amino acid shown in SEQ ID NO:2 or SEQ ID NO: 5, or encoding an amino acid sequence having not less than 98% identity thereto; preferably a polynucleotide comprising replacement of the amino acid corresponding to glutamic acid at position 1202 of SEQ ID NO:2 (position 177 of SEQ ID NO:5) with glycine, replacement of the amino acid corresponding to glutamic acid at position 1056 (position 31 of SEQ ID NO:5) with valine, and replacement of the amino acid corresponding to alanine at position 2199 (position 1174 of SEQ ID NO:5) with threonine.

Polynucleotide derived from novel hepatitis C virus strain and use thereof

The present invention aims to provide hepatitis C virus inhibitors capable of inhibiting viral replication in hepatitis C virus-infected cells. The replication of hepatitis C virus can be inhibited and hepatitis C virus-infected cells can be specifically injured by specifically inhibiting BGT-1 or AKR1C1 involved in the replication of hepatitis C virus. Thus, viral inhibitors comprising a substance inhibiting BGT-1 or AKR1C1 are effective for the treatment of hepatitis C.

Hepatitis C virus inhibitors

Growing community of inventors

Tokyo, Japan

Michinori Kohara